哈卡特
STAT蛋白
炎症
特应性皮炎
车站3
信号转导
免疫学
激活剂(遗传学)
小干扰RNA
STAT6
生物
转录因子
NFKB1型
肿瘤坏死因子α
癌症研究
转染
细胞生物学
白细胞介素4
细胞因子
细胞培养
受体
基因
遗传学
作者
Jie Han,Xinying Cai,Shichun Qin,Zengyunou Zhang,Yuanyuan Wu,Yuanzhe Shi,Tingyue Deng,Benjin Chen,Li Liu,Haisheng Qian,Wen‐Liang Fang,Feng‐Li Xiao
摘要
Our group previously found that the transmembrane protein 232 (TMEM232) gene was associated with atopic dermatitis (AD) by genome-wide association study and fine mapping study. However, its function is unclear so far.To investigate the roles and mechanisms of TMEM232 in AD.The expression of TMEM232 was investigated in skin lesions of patients with AD, the MC903-induced AD mouse model, human primary keratinocytes and immortalized human keratinocyte cell line (HaCaT) cells stimulated with different inflammatory factors. The role of TMEM232 in AD was analysed in HaCaT cells and Tmem232 knockout (Tmem232-/-) mice. Tmem232-specific small interfering RNA (siRNA) was used to evaluate its therapeutic potential in the AD mouse model.The expression of TMEM232 was significantly increased in skin lesions of patients with AD, the MC903-induced AD mouse model and human primary keratinocytes and HaCaT cells stimulated with different inflammatory factors compared with controls. In the presence of MC903, Tmem232-/- mice exhibited significantly reduced dermatitis severity, mast-cell infiltration in the back, and expression of T-helper (Th)1 and Th2-related inflammatory factors in skin tissue compared with wild-type mice. In vitro and in vivo experiments further showed that upregulation of TMEM232 in AD exacerbated the inflammation response through activating the pathway of nuclear factor-κB and signal transducer and activator of transcription (STAT) 3, and was regulated by the interleukin-4/STAT6 axis, which formed a self-amplifying loop. Finally, topical application of Tmem232 siRNA markedly ameliorated AD-like lesions in the AD model.This study is the first to outline the function of TMEM232. It is involved in regulating inflammation in AD and may be a potential target for AD treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI